GlassScriptPhysician profile
Sonia Guirguis
NPI 1215968136
$5,509.95
in general payments reported to CMS, 2019-2025
25 companies · $1,043 in 2025
The $1,043 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $588 · 2020: $345 · 2021: $463 · 2022: $782 · 2023: $1,006 · 2024: $1,283 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,332.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,558.55 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,383.24 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $815.18 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $318.69 | 2019-2025 | Dupixent |
| Genzyme Corporation | $240.82 | 2019-2025 | |
| Amgen INC. | $229.17 | 2022-2025 | Tezspire |
| Kaleo, INC. | $150.86 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $108.52 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $95.39 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $89.18 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.80 | 2019-2023 | Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $78.25 | 2021-2023 | Takhzyro, Hyqvia |
| Ars Pharmaceuticals Operations, INC. | $52.53 | 2025 | Neffy |
| Alk-Abello, INC | $49.24 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $47.06 | 2021-2025 | Orladeyo |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46.37 | 2023 | |
| Incyte Corporation | $36.08 | 2024-2025 | Opzelura |
| Blueprint Medicines Corporation | $30.30 | 2023-2024 | Ayvakit |
| Octapharma USA, INC. | $16.12 | 2022 | |
| Galderma Laboratories, L.P. | $15.00 | 2025 | Nemluvio |
| Paratek Pharmaceuticals, INC. | $14.72 | 2025 | Xhance |
| Leo Pharma INC. | $13.84 | 2022 | |
| Phadia US INC. | $12.83 | 2022 | |
| Boston Scientific Corporation | $12.35 | 2019 | |
| Pfizer INC. | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sonia Guirguis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.